Ctd Holdings Inc (CTDH) 0.7000 $CTDH
CTD Holdings Names New Board Chairman
Marketwire - Wed Oct 01, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of N. Scott Fine as Chairman of the Board of Directors. Mr. Fine, who recently became Vice Chairman and Lead Director, is a seasoned finance executive with more than 35 years of experience in helping public companies to realize their full potential.
CTD Holdings Reports Progress in Orphan Drug Development and Acquires Equity Capital in Second Quarter
Marketwire - Fri Aug 15, 7:04AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies based on cyclodextrin chemistry, today reported continued progress on its orphan drug development in its second-quarter filing with the Securities and Exchange Commission. Validation of the manufacturing process for the Trappsol® Cyclo(TM) product is proceeding as expected, and the Company plans to file its Drug Master File with the Food and Drug Administration in the third quarter. In the second quarter and July, the Company closed on two rounds of private equity totaling $2.725 million.
CTD Holdings raises USD1.725m from private placement in preparation for clinical trials
M2 - Wed Jul 23, 7:12AM CDT
Cyclodextrins supplier CTD Holdings (Other OTC:CTDH) reported on Tuesday the issuance of 1,725,000 shares of common stock in a private placement with a group of qualified private investors led by Novit, an investment arm of US Pharmacia.
CTD Holdings Closes $1.725 Million Private Placement
PRWeb - Tue Jul 22, 11:05AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia.
CTD Holdings announces change in executive roles
M2 - Thu Jul 10, 5:07AM CDT
Cyclodextrin products company CTD Holdings (Other OTC:CTDH) stated on Wednesday that Dr. Jeffrey Tate has been promoted to the chief executive officer role.
CTD Holdings Names New Chief Executive
PRWeb - Wed Jul 09, 11:03AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become Executive Chairman. Dr. Tate has been President of CTD for 3 years and is a seasoned executive with more than 30 years of experience in both academic and industrial biotechnology. Mr. Strattan is the founder of the CTD Holdings Family of Companies and took the company public in 1994.
CTD Holdings announces rise of 176% in net income & 71% in revenues in 2013
M2 - Thu Mar 13, 4:30AM CDT
Cyclodextrins & cyclodextrin supplier CTD Holdings (Other OTC:CTDH) stated on Wednesday its net income of USD205,000 for the fiscal year ended 31 December 2013.
CTD Holdings Reports Record Revenues for 2013
Marketwire - Wed Mar 12, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) reported record product sales of $1,693,335 for the fiscal year ended December 31, 2013, a 71% increase over 2012 product sales. This revenue growth was driven by sales of Trappsol products to existing and new customers. The Company reported net income of $205,000 for 2013, a 176% increase over 2012.
CTD Holdings, Inc. Closes on Private Placement
PRWeb - Thu Feb 20, 3:43AM CST
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer of cyclodextrins for the pharmaceutical and other markets, announced today that it has closed on a private placement of $500,000 with a group of seasoned international investors who are experienced in the consumer and healthcare industries.
OTC Daily Alert Stock Watch - CTD Holdings, Inc (OTCQB: CTDH)
WorldStockWire - Sat Aug 10, 5:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CTD Holdings, Inc. Announces Refinancing of Long Term Debt
PRWeb - Thu Aug 08, 3:34AM CDT
CTD Holdings, Inc. (OTCQB:CTDH) closed on a series of loans through Regions Bank that refinances its existing indebtedness into three notes at favorable interest rates. The three notes consist of: a Mortgage on the company's Alachua, FL property of $578,998 with an interest rate of 3.99%; an Equipment Loan of $295,890 secured by a lien on the company's manufacturing equipment with an interest rate of 3.99%; and a Line of Credit for $100,000 with an interest rate of prime plus 1.8% currently 5.05%. A complete description of the loan package is found in the SEC Form 8K filed July 26, 2013.
CTD Holdings Names New Board Chairman
Marketwire - Wed Oct 01, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of N. Scott Fine as Chairman of the Board of Directors. Mr. Fine, who recently became Vice Chairman and Lead Director, is a seasoned finance executive with more than 35 years of experience in helping public companies to realize their full potential.
CTD Holdings Reports Progress in Orphan Drug Development and Acquires Equity Capital in Second Quarter
Marketwire - Fri Aug 15, 7:04AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies based on cyclodextrin chemistry, today reported continued progress on its orphan drug development in its second-quarter filing with the Securities and Exchange Commission. Validation of the manufacturing process for the Trappsol® Cyclo(TM) product is proceeding as expected, and the Company plans to file its Drug Master File with the Food and Drug Administration in the third quarter. In the second quarter and July, the Company closed on two rounds of private equity totaling $2.725 million.
CTD Holdings raises USD1.725m from private placement in preparation for clinical trials
M2 - Wed Jul 23, 7:12AM CDT
Cyclodextrins supplier CTD Holdings (Other OTC:CTDH) reported on Tuesday the issuance of 1,725,000 shares of common stock in a private placement with a group of qualified private investors led by Novit, an investment arm of US Pharmacia.
CTD Holdings Closes $1.725 Million Private Placement
PRWeb - Tue Jul 22, 11:05AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia.
CTD Holdings announces change in executive roles
M2 - Thu Jul 10, 5:07AM CDT
Cyclodextrin products company CTD Holdings (Other OTC:CTDH) stated on Wednesday that Dr. Jeffrey Tate has been promoted to the chief executive officer role.
CTD Holdings Names New Chief Executive
PRWeb - Wed Jul 09, 11:03AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become Executive Chairman. Dr. Tate has been President of CTD for 3 years and is a seasoned executive with more than 30 years of experience in both academic and industrial biotechnology. Mr. Strattan is the founder of the CTD Holdings Family of Companies and took the company public in 1994.
CTD Holdings announces rise of 176% in net income & 71% in revenues in 2013
M2 - Thu Mar 13, 4:30AM CDT
Cyclodextrins & cyclodextrin supplier CTD Holdings (Other OTC:CTDH) stated on Wednesday its net income of USD205,000 for the fiscal year ended 31 December 2013.
CTD Holdings Reports Record Revenues for 2013
Marketwire - Wed Mar 12, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) reported record product sales of $1,693,335 for the fiscal year ended December 31, 2013, a 71% increase over 2012 product sales. This revenue growth was driven by sales of Trappsol products to existing and new customers. The Company reported net income of $205,000 for 2013, a 176% increase over 2012.
CTD Holdings, Inc. Closes on Private Placement
PRWeb - Thu Feb 20, 3:43AM CST
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer of cyclodextrins for the pharmaceutical and other markets, announced today that it has closed on a private placement of $500,000 with a group of seasoned international investors who are experienced in the consumer and healthcare industries.
OTC Daily Alert Stock Watch - CTD Holdings, Inc (OTCQB: CTDH)
WorldStockWire - Sat Aug 10, 5:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CTD Holdings, Inc. Announces Refinancing of Long Term Debt
PRWeb - Thu Aug 08, 3:34AM CDT
CTD Holdings, Inc. (OTCQB:CTDH) closed on a series of loans through Regions Bank that refinances its existing indebtedness into three notes at favorable interest rates. The three notes consist of: a Mortgage on the company's Alachua, FL property of $578,998 with an interest rate of 3.99%; an Equipment Loan of $295,890 secured by a lien on the company's manufacturing equipment with an interest rate of 3.99%; and a Line of Credit for $100,000 with an interest rate of prime plus 1.8% currently 5.05%. A complete description of the loan package is found in the SEC Form 8K filed July 26, 2013.
